Udenafil: Efficacy and tolerability in the management of erectile dysfunction

Sung gu Kang, je Jong Kim

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalTherapeutic Advances in Urology
Volume5
Issue number2
DOIs
Publication statusPublished - 2013 Apr

Keywords

  • Erectile dysfuction
  • Once-daily dosing
  • Phosphodiesterase type 5
  • Udenafil

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Udenafil: Efficacy and tolerability in the management of erectile dysfunction'. Together they form a unique fingerprint.

  • Cite this